Cancer Research and Treatment

Original Articles

Long-term Immunogenicity of the 13-valent Pneumococcal Conjugate Vaccine during Adjuvant Chemotherapy in Patients with Gastric and Colorectal Cancer: A 5-year Follow-up of a Randomized Controlled Trial: Hyeon-Jong Kim, Hyunjin Bang, Hyun-Jung Shim, Jun Eul Hwang, Sang-Hee Cho, Ik-Joo Chung, Seung Ji Kang, Jong Gwang Kim, Seung-Hoon Beom, A-Yeung Jang, Joon Young Song, Woo Kyun Bae; Received November 12, 2024 Accepted February 11, 2025 Published online February 12, 2025; DOI: https://doi.org/10.4143/crt.2024.1083 [Accepted]

Abstract PDF: Purpose
Current guidelines recommend vaccination at least two weeks before chemotherapy initiation to optimize the immune response despite limited evidence. Our previous study indicated no differences in short-term immune response for the 13-valent pneumococcal conjugate vaccine (PCV13) according to the vaccination timing. This study aims to investigate the long-term efficacy of PCV13 and clinical factors associated with the respective antibody response.
Materials and Methods
Patients with gastric or colorectal cancer who received adjuvant chemotherapy were enrolled and divided into two groups: vaccinated two weeks before chemotherapy (arm A) and vaccinated concurrently with chemotherapy (arm B). Serum samples were collected before vaccination and in one month, three years, and five years. Immune responses were measured using ELISA and multiplex opsonophagocytosis assay.
Results
Including 63 patients, both groups showed an initial increase in the geometric mean titers (GMTs) of opsonophagocytic activity and the geometric mean concentrations (GMCs) of serotype-specific IgG levels after one month, followed by a decline at three and five years, particularly for serotypes 1, 14, 18C, and 19A. Despite the decline, global protection was maintained for five years, although global response decreased. The two arms did not show significant differences in immunogenicity nor in factors such as vaccination timing, age, cancer type, or chemotherapy regimen.
Conclusion
Vaccination timing is not a significant factor for the immunogenicity of PCV13 in cancer patients undergoing adjuvant chemotherapy. Global protection against pneumococcal infection was sustained for >5 years, and global response remained in over half of patients.

4,041 View
50 Download

Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial: Wonyoung Choi, Jong Gwang Kim, Seung-Hoon Beom, Jun-Eul Hwang, Hyun-Jung Shim, Sang-Hee Cho, Min-Ho Shin, Sin-Ho Jung, Ik-Joo Chung, Joon Young Song, Woo Kyun Bae; Cancer Res Treat. 2020;52(1):246-253. Published online July 9, 2019; DOI: https://doi.org/10.4143/crt.2019.189

Abstract PDF Supplementary Material PubReader ePub

Purpose
Pneumococcal vaccination (13-valent pneumococcal conjugate vaccine [PCV13]) is recommended to cancer patients undergoing systemic chemotherapy. However, the optimal time interval between vaccine administration and initiation of chemotherapy has been little studied in adult patients with solid malignancies.
Materials and Methods
We conducted a prospective randomized controlled trial to evaluate whether administering PCV13 on the first day of chemotherapy is non-inferior to vaccinating 2 weeks prior to chemotherapy initiation. Patients were randomly assigned to two study arms, and serum samples were collected at baseline and 4 weeks after vaccination to analyze the serologic response against Streptococcus pneumoniae using a multiplexed opsonophagocytic killing assay.
Results
Of the 92 patients who underwent randomization, 43 patients in arm A (vaccination 2 weeks before chemotherapy) and 44 patients in arm B (vaccination on the first day of chemotherapy) were analyzed. Immunogenicity was assessed by geometric mean and fold-increase of post-vaccination titers, seroprotection rates (percentage of patients with post-vaccination titers > 1:64), and seroconversion rates (percentage of patients with > 4-fold increase in post-vaccination titers). Serologic responses to PCV13 did not differ significantly between the two study arms according to all three types of assessments.
Conclusion
The overall antibody response to PCV13 is adequate in patients with gastric and colorectal cancer during adjuvant chemotherapy, and no significant difference was found when patients were vaccinated two weeks before or on the day of chemotherapy initiation.

Citations

Citations to this article as recorded by

Vaccination of people with solid tumors and diabetes: existing evidence and recommendations. A position statement from a multidisciplinary panel of scientific societies
Marco Gallo, Angioletta Lasagna, Valerio Renzelli, Lelio Morviducci, Alessio Cortellini, Matteo Monami, Giampiero Marino, Stefania Gori, Matteo Verzé, Alberto Ragni, Enzo Tuveri, Laura Sciacca, Stella D’Oronzo, Dario Giuffrida, Annalisa Natalicchio, Franc
Journal of Endocrinological Investigation.2025;[Epub] CrossRef
Italian oncologists and vaccinations against infectious diseases: Results of a survey of the Italian Association of Medical Oncology
Angioletta Lasagna, Antonella Brunello, Nicola Silvestris, Paolo Pedrazzoli, Massimo Di Maio, Saverio Cinieri
Tumori Journal.2024; 110(1): 60. CrossRef
Vaccination of Adults With Cancer: ASCO Guideline
Mini Kamboj, Kari Bohlke, Deana M. Baptiste, Kieron Dunleavy, Abbey Fueger, Lee Jones, Amar H. Kelkar, Lisa Y. Law, Kristine B. LeFebvre, Per Ljungman, Eric D. Miller, Larissa A. Meyer, Heather N. Moore, Heloisa P. Soares, Randy A. Taplitz, Edom S. Woldet
Journal of Clinical Oncology.2024; 42(14): 1699. CrossRef
Cancer bronchopulmonaire
M. Lachâtre, A. Lemaitre, C. Charlier, J. Mazières
Revue des Maladies Respiratoires Actualités.2024; 16: e39. CrossRef
Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)
P. Pedrazzoli, A. Lasagna, I. Cassaniti, A. Piralla, A. Squeri, R. Bruno, P. Sacchi, F. Baldanti, M. Di Maio, G.D. Beretta, S. Cinieri, N. Silvestris
ESMO Open.2023; 8(3): 101215. CrossRef
Pneumococcal Vaccination in Adults: A Narrative Review of Considerations for Individualized Decision-Making
Kay Choong See
Vaccines.2023; 11(5): 908. CrossRef
Uptake of vaccination in older Indian patients with cancer: A cross-sectional observational study
Tabitha M. Sabu, Vanita Noronha, Abhijith R. Rao, Anita Kumar, Shreya Gattani, Anant Ramaswamy, Anupa Pillai, Ratan Dhekale, Renita Castelino, Sharath Kumar, Arshiya Sehgal, Pallavi Rana, Vikram Gota, Rajendra Badwe, Kumar Prabhash
Cancer Research, Statistics, and Treatment.2023; 6(1): 52. CrossRef
Review of Vaccination Recommendations in Guidelines for Non-Communicable Diseases with Highest Global Disease Burden among Adults 75 Years Old and Above
Abdul Rahman Ishak, Yu Chun Hsieh, Harshitha Srinivasan, Kay Choong See
Vaccines.2023; 11(6): 1076. CrossRef
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
Melissa Bersanelli, Elena Verzoni, Alessio Cortellini, Raffaele Giusti, Lorenzo Calvetti, Paola Ermacora, Marilena Di Napoli, Annamaria Catino, Valentina Guadalupi, Giorgia Guaitoli, Vieri Scotti, Francesca Mazzoni, Antonello Veccia, Pamela Francesca Gugl
eClinicalMedicine.2023; 61: 102044. CrossRef
Immunological Assessment of Recent Immunotherapy for Colorectal Cancer
Subhadeep Das, Diptikanta Acharya
Immunological Investigations.2023; 52(8): 1065. CrossRef
Vaccination anti-infectieuse : pour qui ? Quand ? Comment ?
M. Lachâtre, M. Murris-Espin, J. Mazières
Revue des Maladies Respiratoires Actualités.2023; 15(2): 2S209. CrossRef
Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial
Laurie Spehner, Emeline Orillard, Antoine Falcoz, Quentin Lepiller, Adeline Bouard, Hamadi Almotlak, Stefano Kim, Elsa Curtit, Guillaume Meynard, Marine Jary, Charlee Nardin, Kamal Asgarov, Syrine Abdeljaoued, Ugo Chartral, Virginie Mougey, Myriam Ben Khe
BMJ Oncology.2023; 2(1): e000054. CrossRef
Novel Pneumococcal Protein-Polysaccharide Conjugate Vaccine Based on Biotin-Streptavidin
Mengze Guo, Xiaonan Guo, Chenxing Zhang, Shidong Zhu, Yue Zhang, Tiejun Gu, Wei Kong, Yongge Wu, Nancy E. Freitag
Infection and Immunity.2022;[Epub] CrossRef
COVID-19 vaccination in cancer patients: a narrative review
Suranjith L Seneviratne, Pamodh Yasawardene, Widuranga Wijerathne, Buddhika Somawardana
Journal of International Medical Research.2022;[Epub] CrossRef
Invasive pneumococcal disease among adults with hematological and solid organ malignancies: A population-based cohort study
Hannah M. Garcia Garrido, Mirjam J. Knol, Jarom Heijmans, Nina M. van Sorge, Elisabeth A.M. Sanders, Heinz-Josef Klümpen, Martin P. Grobusch, Abraham Goorhuis
International Journal of Infectious Diseases.2021; 106: 237. CrossRef
Can Cancer Survivors Donate Convalescent Plasma for the Treatment of COVID-19?
Ajit Venniyoor
Indian Journal of Medical and Paediatric Oncology.2021; 42(01): 021. CrossRef
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment
M. Peeters, L. Verbruggen, L. Teuwen, G. Vanhoutte, S. Vande Kerckhove, B. Peeters, S. Raats, I. Van der Massen, S. De Keersmaecker, Y. Debie, M. Huizing, P. Pannus, K. Neven, K.K. Ariën, G.A. Martens, M. Van Den Bulcke, E. Roelant, I. Desombere, S. Angui
ESMO Open.2021; 6(5): 100274. CrossRef
Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults
Nobuhiro Asai, Hiroshige Mikamo
Microorganisms.2021; 9(11): 2342. CrossRef
Vaccination practices, efficacy, and safety in adults with cancer
Laboni Sarkar, Vasu Babu Goli, Nandini Menon, Vijay Maruti Patil, Vanita Noronha, Kumar Prabhash
Cancer Research, Statistics, and Treatment.2021; 4(3): 505. CrossRef
Incidence of Invasive Pneumococcal Disease Among Adults With Hematological and Solid Organ Malignancies in the Netherlands: A Population Based Cohort Study
Hannah M. Garcia Garrido, Mirjam J. Knol, J. Heijmans, Nina M. van Sorge, Elisabeth A.M. Sanders, Heinz-Josef Klümpen, Martin P. Grobusch, Abraham Goorhuis
SSRN Electronic Journal .2020;[Epub] CrossRef

7,978 View
270 Download
16 Web of Science
20 Crossref

Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer: Jin Won Kim, Jong Gwang Kim, Byung Woog Kang, Ik-Joo Chung, Young Seon Hong, Tae-You Kim, Hong Suk Song, Kyung Hee Lee, Dae Young Zang, Yoon Ho Ko, Eun-Kee Song, Jin Ho Baek, Dong‐Hoe Koo, So Yeon Oh, Hana Cho, Keun-Wook Lee; Cancer Res Treat. 2019;51(1):223-239. Published online October 19, 2018; DOI: https://doi.org/10.4143/crt.2018.073

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to evaluate chemotherapy patterns and changes in quality of life (QOL) during first-line palliative chemotherapy for Korean patients with unresectable or metastatic/recurrent gastric cancer (GC).
Materials and Methods
Thiswas a non-interventional, multi-center, prospective, observational study of 527 patients in Korea. QOL assessments were conducted using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)-C30 and QLQ-STO22 every 3 months over a 12-month period during first-line palliative chemotherapy. The specific chemotherapy regimens were selected by individual clinicians.
Results
Most patients (93.2%) received combination chemotherapy (mainly fluoropyrimidine plus platinum) as their first-line palliative chemotherapy. The median progression-free survival and overall survival were 8.2 and 14.8 months, respectively. Overall, “a little” changes (differences of 5-10 points from baseline)were observed in some of the functioning or symptom scales; none of the QOL scales showed either “moderate” or “very much” change (i.e., ≥ 11 point difference from baseline). When examining the best change in each QOL domain from baseline, scales related to some aspects of functioning, global health status/QOL, and most symptoms revealed significant improvements (p < 0.05). Throughout the course of first-line palliative chemotherapy, most patients’ QOL was maintained to a similar degree, regardless of their actual response to chemotherapy.
Conclusion
This observational study provides important information on the chemotherapy patterns and QOL changes in Korean patientswith advanced GC. Overall, first-line palliative chemotherapy was found to maintain QOL, and most parameters showed an improvement compared with the baseline at some point during the course.

Citations

Citations to this article as recorded by

Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer
Z.A. Wainberg, P.C. Enzinger, S. Qin, K. Yamaguchi, J. Wang, X. Zhou, A. Gnanasakthy, K. Taylor, A. Yusuf, I. Majer, A. Jamotte, Y.-K. Kang
ESMO Gastrointestinal Oncology.2024; 6: 100095. CrossRef
Impact of systemic cancer treatment on quality of life and mental well-being: a comparative analysis of patients with localized and advanced cancer
Adán Rodríguez-Gonzalez, Alberto Carmona-Bayonas, Raquel Hernandez San Gil, Patricia Cruz-Castellanos, Mónica Antoñanzas-Basa, David Lorente-Estelles, María Jose Corral, Manuel González-Moya, Oscar Alfredo Castillo-Trujillo, Emilio Esteban, Paula Jiménez-
Clinical and Translational Oncology.2023; 25(12): 3492. CrossRef
Reminiscence therapy-based care program alleviates anxiety and depression, as well as improves the quality of life in recurrent gastric cancer patients
Xing Wu, Weiwei Zhang
Frontiers in Psychology.2023;[Epub] CrossRef
Toxicities and Quality of Life during Cancer Treatment in Advanced Solid Tumors
Eun Mi Lee, Paula Jiménez-Fonseca, Rocio Galán-Moral, Sara Coca-Membribes, Ana Fernández-Montes, Elena Sorribes, Esmeralda García-Torralba, Laura Puntí-Brun, Mireia Gil-Raga, Juana Cano-Cano, Caterina Calderon
Current Oncology.2023; 30(10): 9205. CrossRef
Psychosocial functioning in individuals with advanced oesophago-gastric cancer: a mixed methods systematic review
Cara Ghiglieri, Martin Dempster, Sam Wright, Lisa Graham-Wisener
BMC Palliative Care.2023;[Epub] CrossRef
Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)
Keun-Wook Lee, Ik-Joo Chung, Min-Hee Ryu, Young Iee Park, Byung-Ho Nam, Ho-Suk Oh, Kyung Hee Lee, Hye Sook Han, Bong-Gun Seo, Jae-Cheol Jo, Hyo Rak Lee, Jin Won Kim, Sook Ryun Park, Sang Hee Cho, Yoon-Koo Kang
Gastric Cancer.2021; 24(1): 156. CrossRef
Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial
Kazumasa Fujitani, Kohei Shitara, Atsuo Takashima, Keisuke Koeda, Hiroki Hara, Norisuke Nakayama, Shuichi Hironaka, Kazuhiro Nishikawa, Yutaka Kimura, Kenji Amagai, Hisashi Hosaka, Yoshito Komatsu, Ken Shimada, Ryohei Kawabata, Hideki Ohdan, Yasuhiro Kode
Gastric Cancer.2021; 24(2): 467. CrossRef
Quality-of-Life Assessment in Patients Receiving Palliative Chemotherapy: Call for Action
Maheswari Senthil
Annals of Surgical Oncology.2021; 28(1): 7. CrossRef
Impact of gastric cancer treatment on quality of life of patients
Kerstin Schütte, Christian Schulz, Kristina Middelberg-Bisping
Best Practice & Research Clinical Gastroenterology.2021; 50-51: 101727. CrossRef
Influencing Factors and Effects of Treatment on Quality of Life in Patients With Gastric Cancer—A Systematic Review
Sophia Kristina Rupp, Andreas Stengel
Frontiers in Psychiatry.2021;[Epub] CrossRef
Chronological changes in quality of life and body composition after gastrectomy for locally advanced gastric cancer
Ki Bum Park, Ji Yeon Park, Seung Soo Lee, Ho Young Chung, Oh Kyoung Kwon
Annals of Surgical Treatment and Research.2020; 98(5): 262. CrossRef
Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome
Hannah Christina Puhr, Eleonore Pablik, Anna Sophie Berghoff, Gerd Jomrich, Sebastian Friedrich Schoppmann, Matthias Preusser, Aysegül Ilhan-Mutlu
ESMO Open.2020; 5(2): e000623. CrossRef

11,959 View
238 Download
12 Web of Science
12 Crossref

The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy: Hyun-Jeong Shim, Min-Ho Shin, Hee-Nam Kim, Jo-Heon Kim, Jun-Eul Hwang, Woo-Kyun Bae, Ik-Joo Chung, Sang-Hee Cho; Cancer Res Treat. 2016;48(1):71-79. Published online May 14, 2015; DOI: https://doi.org/10.4143/crt.2015.018

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to investigate the role of fibroblast growth factor receptor 4 (FGFR4) polymorphism in esophageal cancer after chemoradiotherapy (CRT).
Materials and Methods
Peripheral blood samples from 244 patients treated with CRT for esophageal squamous cell carcinoma were assessed for the role of FGFR4 genotype on treatment response and survival.
Results
A total of 94 patients were homozygous for the Gly388 allele, and 110 were heterozygous and 40 homozygous for the Arg388 allele. No significant association was found between the FGFR4 genotype and clinicopathological parameters. However, patients carrying the Gly388 allele showed a better overall response rate than Arg388 carriers (p=0.038). In addition, Gly388 allele patients at an earlier stage showed better overall survival (OS) and progression-free survival than Arg388 carriers. Among these, the Gly388 allele showed significantly improved OS compared to Arg388 carriers in the lymph node (LN) metastasis group (p=0.042) compared to the no LN metastasis group (p=0.125). However, similar survival outcomes were observed for advanced-stage disease regardless of genotype.
Conclusion
This result suggests that the role of FGFR4 Gly388 in treatment outcomes differs according to esophageal cancer stage. It showed a predictive role in the response of esophageal cancer patients to CRT with a better trend for OS in Gly388 than Arg388 carriers in the early stages. In particular, LN-positive early-stage patients carrying the Gly388 allele showed improved OS compared to those carrying Arg388.

Citations

Citations to this article as recorded by

Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas
Gerd Jomrich, Xenia Hudec, Felix Harpain, Daniel Winkler, Gerald Timelthaler, Thomas Mohr, Brigitte Marian, Sebastian F. Schoppmann
Cells.2019; 8(9): 1092. CrossRef
Association of Fibroblast Growth Factor Receptor 4 Genetic Polymorphisms With the Development of Uterine Cervical Cancer and Patient Prognosis
Tze-Ho Chen, Shun-Fa Yang, Yu-Fan Liu, Wea-Lung Lin, Chih-Ping Han, Po-Hui Wang
Reproductive Sciences.2018; 25(1): 86. CrossRef
Prognostic implications of fibroblast growth factor receptor 4 polymorphisms in primary breast cancer
Wei Wei, Zilong You, Shanshan Sun, Yuhang Wang, Xianyu Zhang, Da Pang, Yongdong Jiang
Molecular Carcinogenesis.2018; 57(8): 988. CrossRef
FGFR4 Arg388 Is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal Transition
Sang Hee Cho, Chang Soo Hong, Hee Nam Kim, Min Ho Shin, Ka Rham Kim, Hyun Jeong Shim, Jun Eul Hwang, Woo Kyun Bae, Ik Joo Chung
Cancer Research and Treatment.2017; 49(3): 766. CrossRef
Association between FGFR4 gene polymorphism and high-risk HPV infection cervical cancer
Ya-Ping Li, Lin Zhang, Yu-Liang Zou, Yan Yu
Asian Pacific Journal of Tropical Medicine.2017; 10(7): 680. CrossRef
Identification of NCCRP1 as an epigenetically regulated tumor suppressor and biomarker for malignant phenotypes of squamous cell carcinoma of the esophagus
Takashi Miwa, Mitsuro Kanda, Masahiko Koike, Naoki Iwata, Haruyoshi Tanaka, Shinichi Umeda, Chie Tanaka, Daisuke Kobayashi, Masamichi Hayashi, Suguru Yamada, Tsutomu Fujii, Michitaka Fujiwara, Yasuhiro Kodera
Oncology Letters.2017; 14(4): 4822. CrossRef
Roles of FGFR in oral carcinogenesis
Xiaoyan Xie, Zhiyong Wang, Fangman Chen, Yao Yuan, Jiayi Wang, Rui Liu, Qianming Chen
Cell Proliferation.2016; 49(3): 261. CrossRef
Predictive role of Host Constitutive Variants in Neoadjuvant Therapy of Esophageal Cancer
Enrica Rumiato, Elisa Boldrin, Alberto Amadori, Daniela Saggioro
Pharmacogenomics.2016; 17(7): 805. CrossRef
Adherens junctions associated protein 1 serves as a predictor of recurrence of squamous cell carcinoma of the esophagus
Haruyoshi Tanaka, Mitsuro Kanda, Masahiko Koike, Naoki Iwata, Dai Shimizu, Kazuhiro Ezaka, Satoshi Sueoka, Yuri Tanaka, Hideki Takami, Ryoji Hashimoto, Chie Tanaka, Suguru Yamada, Tsutomu Fujii, Goro Nakayama, Hiroyuki Sugimoto, Michitaka Fujiwara, Yasuhi
International Journal of Oncology.2015;[Epub] CrossRef

11,952 View
77 Download
12 Web of Science
9 Crossref

Clinical Prognostic Factors for Locally Advanced Esophageal Squamous Carcinoma Treated after Definitive Chemoradiotherapy: Dae-Eun Kim, Uh-Jin Kim, Won-Young Choi, Mi-Young Kim, Seung-Hun Kim, Min-Jee Kim, Hyun-Jeong Shim, Jun-Eul Hwang, Woo-Kyun Bae, Ik-Joo Chung, Taek-Keun Nam, Kook-Joo Na, Sang-Hee Cho; Cancer Res Treat. 2013;45(4):276-284. Published online December 31, 2013; DOI: https://doi.org/10.4143/crt.2013.45.4.276

Abstract PDF PubReader ePub

PURPOSE
Locally advanced esophageal cancers are generally treated with neoadjuvant chemoradiotherapy, followed by surgery in operable candidates. However, even if the patients were diagnosed as operable disease, surgery could not be performed on patients with poor condition or other comorbidity. In this case, definitive chemoradiotherapy (dCRT) is the other option for localized esophageal cancer. Therefore, the purpose of this study was to evaluate the efficacy and clinical prognostic factors for dCRT in locally advanced esophageal cancer.
MATERIALS AND METHODS
We conducted a review of patients who received dCRT for locally advanced squamous esophageal cancer from 2004 to 2010, focusing on stages III and IVa. All patients received at least two cycles of platinum-based chemotherapy during radiation, and all tumor burdens were included in the radiation field. The treatment results were analyzed for patterns of failure and prognostic factors associated with survival.
RESULTS
In total, 63 patients were enrolled in this study. The overall response rate was 84.1%. Relief from dysphagia after dCRT was achieved in 48 patients. The most frequent failure was local recurrence. The median overall survival (OS) was 23.0 months, and the 2-year survival rate was 45.4%. Similar results were observed for elderly study patients. Significant prognostic factors for OS were duration of smoking, high grade of dysphagia (score of 3 or 4), and shorter duration of progression-free and dysphagia-free survival. Maintenance chemotherapy after dCRT did not influence OS. However, "good risk" patients receiving maintenance chemotherapy showed better OS than those who did not receive maintenance chemotherapy (30.4 months vs. 12.0 months, p=0.002).
CONCLUSION
dCRT has a major role in improving survival and palliation of dysphagia in inoperable advanced esophageal cancer, even in elderly patients. Maintenance chemotherapy after dCRT may be effective in prolonging survival in "good risk" patients.

Citations

Citations to this article as recorded by

Maintenance chemotherapy for esophageal squamous cell carcinoma after standard concurrent chemoradiotherapy: a national propensity score matching cohort study
Szu-Wen Tseng
American Journal of Cancer Research.2024; 14(5): 2300. CrossRef
Re-irradiation for local primary-recurrence esophageal squamous cell carcinoma treated with IMRT/VMAT
Geng Xiang, Chunsheng Xu, Guangjin Chai, Bo Lyu, Zhaohui Li, Bin Wang, Mei Shi, Lina Zhao
Radiation Oncology.2023;[Epub] CrossRef
Prognostic factors for 495 nonoperative esophageal squamous cancer patients receiving IMRT plus chemotherapy: A retrospective analysis
Q. Gao, Z.-Y. Liu, Y. Cheng, X.-K. Di, Y.-M. Zhang, X.-C. Sun, X.-J. Xia, X.-L. Ge
Cancer/Radiothérapie.2022; 26(8): 1002. CrossRef
Irradiation-induced exosomal HMGB1 to confer radioresistance via the PI3K/AKT/FOXO3A signaling pathway in ESCC
Xingyu Du, Xueyuan Zhang, Jing Dong, Naiyi Zou, Dong Guo, Weinan Yao, Xiaobin Wang, Shuguang Li, Chunyang Song, Ke Yan, Wenbin Shen, Shuchai Zhu
Journal of Translational Medicine.2022;[Epub] CrossRef
A comparison between raltitrexed plus cisplatin and docetaxel plus cisplatin in concurrent chemoradiation for non-surgical esophageal squamous cell carcinoma
X. Xia, Z. Liu, B. Cai, X. Di, X. Sun, X. Ge
Cancer/Radiothérapie.2021; 25(1): 39. CrossRef
Long-Term Survival in Nonsurgical Esophageal Cancer Patients Who Received Consolidation Chemotherapy Compared With Patients Who Received Concurrent Chemoradiotherapy Alone: A Systematic Review and Meta-Analysis
Xiaojie Xia, Zeyuan Liu, Qin Qin, Xiaoke Di, Zhaoyue Zhang, Xinchen Sun, Xiaolin Ge
Frontiers in Oncology.2021;[Epub] CrossRef
High incidence of esophageal fistula on patients with clinical T4b esophageal squamous cell carcinoma who received chemoradiotherapy: A retrospective analysis
Baoqing Chen, Meiling Deng, Chen Yang, Mihnea P. Dragomir, Lei Zhao, Kunhao Bai, Mian Xi, Yonghong Hu, Yujia Zhu, Qiaoqiao Li
Radiotherapy and Oncology.2021; 158: 191. CrossRef
Prognostic Significance of Interim Response Evaluation during Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Jun Gi Yeom, Jie-Hyun Kim, Jun Won Kim, Yeona Cho, Ik Jae Lee, Chang Geol Lee, Jaeyoung Chun, Young Hoon Youn, Hyojin Park
Cancers.2021; 13(6): 1255. CrossRef
Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
Xi-Lei Zhou, Chang-Hua Yu, Wan-Wei Wang, Fu-Zhi Ji, Yao-Zu Xiong, Wei-Guo Zhu, Yu-Suo Tong
Radiation Oncology.2021;[Epub] CrossRef
Clinical Outcomes and Prognostic Factors of Salvage Treatment for Local Lymph Node Recurrence After Radical Resection of Oesophageal Carcinoma
Liang Gu, Yangchen Liu, Hongxue Ye, Fei Gao, Xiaoxiang Yin, Ying Zhao, Ye Tian
Cancer Management and Research.2021; Volume 13: 5845. CrossRef
Chemoradiotherapy Is Superior to Radiotherapy Alone in Esophageal Cancer Patients Older Than 65 Years: A Propensity Score-Matched Analysis of the SEER Database
Xiaojie Xia, Qing Gao, Xiaolin Ge, Zeyuan Liu, Xiaoke Di, Xinchen Sun, Yan Yang
Frontiers in Oncology.2021;[Epub] CrossRef
Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis
Jianing Wang, Linlin Xiao, Shuai Wang, Qingsong Pang, Jun Wang
Frontiers in Oncology.2021;[Epub] CrossRef
Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients
Ao Liu, Yalin Wang, Xin Wang, Liqiong Zhu, Yu Nie, Minghuan Li
Radiation Oncology.2021;[Epub] CrossRef
Survival Comparision of Three-dimensional Radiotherapy Alone vs. Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
An-Du Zhang, Xiao-Hua Su, Gao-Feng Shi, Chun Han, Lan Wang, Hui Liu, Jun Zhang, Ruo-Hui Zhang
Archives of Medical Research.2020; 51(5): 419. CrossRef
Evaluating the optimal re-irradiation dose for locally recurrent esophageal squamous cell carcinoma after definitive radiotherapy
Xiujuan Xu, Zhongming Wang, Shunian Jiang, Yuping Shang, Yan Wu
Radiation Oncology.2019;[Epub] CrossRef
Prognosis impact of clinical characteristics in patients with inoperable esophageal squamous cell carcinoma
Ying Yang, Jun Jia, Zhiwei Sun, Feng Du, Jing Yu, Chuanling Liu, Yanjie Xiao, Xiaodong Zhang, Qingyi Wei
PLOS ONE.2017; 12(8): e0182660. CrossRef
The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy
Hyun-Jeong Shim, Min-Ho Shin, Hee-Nam Kim, Jo-Heon Kim, Jun-Eul Hwang, Woo-Kyun Bae, Ik-Joo Chung, Sang-Hee Cho
Cancer Research and Treatment.2016; 48(1): 71. CrossRef
Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer
Yong-Hyub Kim, Sang-Yun Song, Hyun-Jeong Shim, Woong-Ki Chung, Sung-Ja Ahn, Mee Sun Yoon, Jae-Uk Jeong, Ju-Young Song, Taek-Keun Nam
Radiation Oncology Journal.2015; 33(1): 12. CrossRef
Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer
Eun Jin Yoo, Jun Chul Park, Eun Hye Kim, Chan Hyuk Park, Choong Nam Shim, Hyun Jik Lee, Hyun Soo Chung, Hyuk Lee, Sung Kwan Shin, Sang Kil Lee, Chang Geol Lee, Yong Chan Lee
Digestive and Liver Disease.2014; 46(9): 846. CrossRef

13,087 View
92 Download
19 Crossref

Case Report

Reversible Proximal Renal Tubular Dysfunction after One-Time Ifosfamide Exposure: Young Il Kim, Ju Young Yoon, Jun Eul Hwang, Hyun Jeong Shim, Woo Kyun Bae, Sang Hee Cho, Ik-Joo Chung; Cancer Res Treat. 2010;42(4):244-246. Published online December 31, 2010; DOI: https://doi.org/10.4143/crt.2010.42.4.244

Abstract PDF PubReader ePub

The alkylating agent ifosfamide is an anti-neoplastic used to treat various pediatric and adult malignancies. Its potential urologic toxicities include glomerulopathy, tubulopathy and hemorrhagic cystitis. This report describes a case of proximal renal tubular dysfunction and hemorrhagic cystitis in a 67-year-old male given ifosfamide for epitheloid sarcoma. He was also receiving an oral hypoglycemic agent for type 2 diabetes mellitus and had a baseline glomerular filtration rate of 51.5 mL/min/1.73 m². Despite mesna prophylaxis, the patient experienced dysuria and gross hematuria after a single course of ifosfamide plus adriamycin. The abrupt renal impairment and serum/urine electrolyte imbalances that ensued were consistent with Fanconi's syndrome. However, normal renal function and electrolyte status were restored within 14 days, simply through supportive measures. A score of 8 by Naranjo adverse drug reaction probability scale indicated these complications were most likely treatment-related, although they developed without known predisposing factors. The currently undefined role of diabetic nephropathy in adult ifosfamide nephrotoxicity merits future investigation.

Citations

Citations to this article as recorded by

Ifosfamide-induced nephrotoxicity in oncological patients
Juan Eduardo Quiroz-Aldave, María Del Carmen Durand-Vásquez, Freddy Shanner Chávez-Vásquez, Alexandra Noelia Rodríguez-Angulo, Sonia Elizabeth Gonzáles-Saldaña, Carlos César Alcalde-Loyola, Julia Cristina Coronado-Arroyo, Francisca Elena Zavaleta-Gutiérre
Expert Review of Anticancer Therapy.2024; 24(1-2): 5. CrossRef
Conditioning Regimens for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Stem Cell Transplantation: BEAM Versus High Dose ICE
Ahmet Kursad Gunes, Simten Dagdas, Funda Ceran, Mehmet Ali Ucar, Mesude Falay, Cenk Sunu, Meltem Ayli, Nurullah Zengin, Gulsum Ozet
Indian Journal of Hematology and Blood Transfusion.2021; 37(1): 82. CrossRef
Cancer treatment-induced bone loss (CTIBL): Pathogenesis and clinical implications
S. D’Oronzo, S. Stucci, M. Tucci, F. Silvestris
Cancer Treatment Reviews.2015; 41(9): 798. CrossRef
Tubulointerstitial nephritis and cancer chemotherapy: update on a neglected clinical entity
M. Airy, R. Raghavan, L. D. Truong, G. Eknoyan
Nephrology Dialysis Transplantation.2013; 28(10): 2502. CrossRef

8,556 View
57 Download
4 Crossref

Original Articles

Coexisting with Clonal Evolution and BCR-ABL Mutant in CML Patients Treated with Second-generation Tyrosine Kinase Inhibitors Predict the Discrepancy of in vitro Drug Sensitivity: Jae-Sook Ahn, Yeo-Kyeoung Kim, Se Ryeon Lee, Li Yu, Deok-Hwan Yang, Sang-Hee Cho, Hyun Jeong Shim, Woo Kyun Bae, Je-Jung Lee, Ik-Joo Chung, Myung Gun Shin, Hyeoung-Joon Kim; Cancer Res Treat. 2010;42(1):37-41. Published online March 31, 2010; DOI: https://doi.org/10.4143/crt.2010.42.1.37

Abstract PDF PubReader ePub

Purpose

Second-generation tyrosine kinase inhibitors (second TKIs) such as nilotinib and dasatinib control the activity of most ABL kinase domain mutations observed in patients with imatinib resistance. Although in vitro data show that both agents can inhibit all mutations except T315I, some discrepancies have been observed in a small subset of mutation clones. Cytogenetic clonal evolution is the important resistance mechanism of chronic myeloid leukemia (CML). Accordingly, we observed the clinical significance of coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second TKIs.

Materials and Methods

We monitored BCR-ABL transcript kinetics, interrelationship of clones expressing non-mutated and mutant transcripts and clonal aberrations within Philadelphia (Ph) positive and negative clones, respectively, in eight patients with CML receiving dasatinib or nilotinib for 3~41 months.

Results

Clinical responses were correlated with in vitro sensitivity of the BCR-ABL mutants to the second TKIs in four patients. Four patients showed resistance to the second TKIs as compared to in vitro observations; three of them developed chromosomal abnormalities in the Ph chromosome positive or negative metaphases. Another patient lost the original mutation but acquired a more resistant new mutation and became resistant to the second TKI.

Conclusion

Cytogenetic clonal evolution is an independent poor prognostic factor in CML, which could explain the onset of mechanisms for second TKIs resistance to ABL kinase domain mutations. The results indicate that an additional evaluation of chromosomal abnormalities is warranted when BCR-ABL mutants are more resistant than indicated by in vitro data.

Citations

Citations to this article as recorded by

T315I – a gatekeeper point mutation and its impact on the prognosis of chronic myeloid leukemia
Bushra Kaleem, Sadaf Shahab, Tahir Sultan Shamsi
Advances in Laboratory Medicine / Avances en Medicina de Laboratorio.2024; 5(4): 412. CrossRef
Impacto de la mutación T315I en el pronóstico de la leucemia mieloide crónica
Bushra Kaleem, Sadaf Shahab, Tahir Sultan Shamsi
Advances in Laboratory Medicine / Avances en Medicina de Laboratorio.2024; 5(4): 418. CrossRef
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
T P Hughes, G Saglio, A Quintás-Cardama, M J Mauro, D-W Kim, J H Lipton, M B Bradley-Garelik, J Ukropec, A Hochhaus
Leukemia.2015; 29(9): 1832. CrossRef

10,898 View
53 Download
3 Crossref

Optimization and Limitation of Calcium Ionophore to Generate DCs from Acute Myeloid Leukemic Cells: Thanh-Nhan Nguyen Pham, Bo-Hwa Choi, Hyun-Kyu Kang, Chun-Chi Jin, Nguyen Hoang Tuyet Minh, Sang-Ki Kim, Jong-Hee Nam, Deok-Hwan Yang, Yeo-Kyeoung Kim, Hyeoung-Joon Kim, Ik-Joo Chung, Je-Jung Lee; Cancer Res Treat. 2007;39(4):175-180. Published online December 31, 2007; DOI: https://doi.org/10.4143/crt.2007.39.4.175

Abstract PDF PubReader ePub

Purpose

Calcium ionophore (CI) is used to generate dendritic cells (DCs) from progenitor cells, monocytes, or leukemic cells. The aim of this study was to determine the optimal dose of CI and the appropriate length of cell culture required for acute myeloid leukemia (AML) cells and to evaluate the limitations associated with CI.

Materials and Methods

To generate leukemic DCs, leukemic cells (4×10⁶ cells) from six AML patients were cultured with various concentrations of CI and/or IL-4 for 1, 2 or 3 days.

Results

Potent leukemic DCs were successfully generated from all AML patients, with an average number of 1.2×10⁶ cells produced in the presence of CI (270 ng/ml) for 2 days. Several surface molecules were clearly upregulated in AML cells supplemented with CI and IL-4, but not CD11c. Leukemic DCs cultured with CI had a higher allogeneic T cell stimulatory capacity than untreated AML cells, but the addition of IL-4 did not augment the MLR activity of these cells. AML cells cultured with CI in the presence or absence of IL-4 showed increased levels of apoptosis in comparison to primary cultures of AML cells.

Conclusion

Although CI appears to be advantageous in terms of time and cost effectiveness, the results of the present study suggest that the marked induction of apoptosis by CI limits its application to the generation of DCs from AML cells.

Citations

Citations to this article as recorded by

The plasticity and potential of leukemia cell lines to differentiate into dendritic cells
QINGWEI GUO, LELING ZHANG, FU LI, GUOSHENG JIANG
Oncology Letters.2012; 4(4): 595. CrossRef

9,416 View
55 Download
1 Crossref

The Efficacy of an Induction Chemotherapy Combination with Docetaxel, Cisplatin, and 5-FU Followed by Concurrent Chemoradiotherapy in Advanced Head and Neck Cancer: Jae-Sook Ahn, Sang-Hee Cho, Ok-Ki Kim, Joon-Kyoo Lee, Deok-Hwan Yang, Yeo-Kyeoung Kim, Je-Jung Lee, Sang-Chul Lim, Hyeoung-Joon Kim, Woong-Ki Chung, Ik-Joo Chung; Cancer Res Treat. 2007;39(3):93-98. Published online September 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.3.93

Abstract PDF PubReader ePub

Purpose

This study was performed to determine the feasibility and safety of the use of induction chemotherapy combined with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by concurrent chemoradiation therapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Materials and Methods

The patients, that were initially not treated for locally advanced SCCHN, underwent three cycles of induction chemotherapy every 3 weeks at a dose of 70 mg/m² docetaxel D1, 75 mg/m² cisplatin D1, 1000 mg/m² 5-FU D1-4, and subsequently received concurrent chemoradiation therapy.

Results

Forty-nine patients were enrolled in this study and forty-three of the patients completed the treatment. The median duration of follow-up was 18 months (range, 6~39 months). All of the patients had stage III (26.5%) or IV (73.5%) squamous cell carcinoma. After sequential therapy, a complete response and partial response was seen in 28 (65.2%) and 13 (30.2%) patients, respectively. The overall response rate was 95.4%. Overall survival and progression-free survival (PFS) at 2 years were 88.7% and 69.7%, respectively. Grade 3~4 neutropenia occurred in 42.2% of the patients and grade 4 thrombocytopenia in 1 cycle (0.7%). Two patients (4.1%) died during the induction chemotherapy due to pneumonia and a subdural hemorrhage, respectively. The group of patients over 65 years of age showed a significant lower dose intensity than that of patients under 65 years of age, but PFS was not significantly different between two groups (p=0.105).

Conclusion

TPF induction chemotherapy followed by concurrent chemoradiotherapy showed a high level of CR and moderate treatment-induced toxicity. Adequate dose modification in elderly patients should be considered to maintain efficacy and avoid treatment-related toxicity.

Citations

Citations to this article as recorded by

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial
Yungan TAO, Xu-Shan Sun, Yoann Pointreau, Christophe Le Tourneau, Christian Sire, Marie-Christine Kaminsky, Alexandre Coutte, Marc Alfonsi, Benôit Calderon, Pierre Boisselier, Laurent Martin, Jessica Miroir, Jean-Francois Ramee, Jean-Pierre Delord, Floria
European Journal of Cancer.2023; 183: 24. CrossRef
Serum Levels of Stromal Cell-Derived Factor-1α and Vascular Endothelial Growth Factor Predict Clinical Outcomes in Head and Neck Squamous Cell Carcinoma Patients Receiving TPF Induction Chemotherapy
Yen-Hao Chen, Chih-Yen Chien, Yu-Ming Wang, Shau-Hsuan Li
Biomedicines.2022; 10(4): 803. CrossRef
Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study
Ching-Yun Hsieh, Ming-Yuh Lein, Shih-Neng Yang, Yao-Ching Wang, Yin-Jun Lin, Chen-Yuan Lin, Chun-Hung Hua, Ming-Hsul Tsai, Ching-Chan Lin
BMC Cancer.2020;[Epub] CrossRef
Neutrophil lymphocyte ratio is an independent prognosticator in patients with locally advanced head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil
Hsiang-Lan Lai, Yeh Tang, Chih-Yen Chien, Fu-Min Fang, Tai-Lin Huang, Tai-Jan Chiu, Shau-Hsuan Li
Journal of Cancer Research and Practice.2019; 6(4): 170. CrossRef
Influence of a dosing-time on toxicities induced by docetaxel, cisplatin and 5-fluorouracil in patients with oral squamous cell carcinoma; a cross-over pilot study
Yoshiyuki Tsuchiya, Kentaro Ushijima, Tadahide Noguchi, Naruo Okada, Jun-ichi Hayasaka, Yoshinori Jinbu, Hitoshi Ando, Yoshiyuki Mori, Mikio Kusama, Akio Fujimura
Chronobiology International.2018; 35(2): 289. CrossRef
Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology
D. Alterio, M. Cossu Rocca, W. Russell-Edu, S. Dicuonzo, G. Fanetti, G. Marvaso, L. Preda, S. Zorzi, E. Verri, F. Nole’, B. A. Jereczek-Fossa
Medical Oncology.2017;[Epub] CrossRef
Clinical study on collagen gel droplet-embedded culture drug sensitivity test for multidrug combination chemotherapy and super selective intra-arterial infusion chemoradiotherapy in oral squamous cell carcinoma
Kaname Sakuma, Ryuki Tamura, Shintaro Hanyu, Haruka Takahashi, Hideaki Sato, Takahiro Oneyama, Akira Yamaguchi, Akira Tanaka
Molecular and Clinical Oncology.2017;[Epub] CrossRef
Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil
Shau‐Hsuan Li, Wei‐Che Lin, Tai‐Lin Huang, Chang‐Han Chen, Tai‐Jan Chiu, Fu‐Min Fang, Wan‐Ting Huang, Cheng‐Ming Hsu, Sheng‐Dean Luo, Chi‐Chih Lai, Yan‐Ye Su, Hui‐Ching Chuang, Chih‐Yen Chien
Head & Neck.2016;[Epub] CrossRef
Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil
Yan-Ye Su, Chih-Yen Chien, Sheng-Dean Luo, Tai-Lin Huang, Wei-Che Lin, Fu-Min Fang, Tai-Jan Chiu, Yen-Hao Chen, Chi-Chih Lai, Cheng-Ming Hsu, Shau-Hsuan Li
World Journal of Surgical Oncology.2016;[Epub] CrossRef
Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma
Hironori Cho, Suetaka Nishiike, Yoshifumi Yamamoto, Yukinori Takenaka, Susumu Nakahara, Toshimichi Yasui, Atsushi Hanamoto, Hidenori Inohara
Auris Nasus Larynx.2015; 42(5): 396. CrossRef
Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck
Woo Kyun Bae, Jun Eul Hwang, Hyun Jeong Shim, Sang Hee Cho, Ki Hyeong Lee, Hye Suk Han, Eun-Kee Song, Hwan Jung Yun, In Sung Cho, Joon Kyoo Lee, Sang-Chul Lim, Woong-Ki Chung, Ik-Joo Chung
BMC Cancer.2013;[Epub] CrossRef
Adjuvant Postoperative Radiotherapy with or without Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: The Importance of Patient Selection for the Postoperative Chemoradiotherapy
Jong Hoon Lee, Jin Ho Song, Sang Nam Lee, Jin Hyoung Kang, Min Sik Kim, Dong Il Sun, Yeon-Sil Kim
Cancer Research and Treatment.2013; 45(1): 31. CrossRef
A case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case
Daisuke Iitaka, Atsushi Shiozaki, Hitoshi Fujiwara, Daisuke Ichikawa, Kazuma Okamoto, Shuhei Komatsu, Yasutoshi Murayama, Hisashi Ikoma, Yoshiaki Kuriu, Masayoshi Nakanishi, Toshiya Ochiai, Yukihito Kokuba, Teruhisa Sonoyama, Eigo Otsuji
Surgery Today.2013; 43(5): 556. CrossRef
Usefulness and Indication of Superselective Intra-arterial Chemotherapy via the Radial Artery for Advanced Head and Neck Cancer^|^mdash;a Indication for Inaccessible to Treatment with Seldingers Method^|^mdash;
Junkichi Yokoyama, Shin Ito, Shinichi Ohba, Mitsuhisa Fujimaki, Katsuhisa Ikeda, Makoto Hanaguri
Nippon Jibiinkoka Gakkai Kaiho.2012; 115(6): 625. CrossRef
Examination on the Effect of Docetaxel Dilution Concentration on the Hypersensitivity Revelation Rate
Tatsuya Hayama, Masatoshi Hayasaka, Mei Onuma, Toshimitsu Nakayama, Sadao Amano, Yoshikazu Yoshida
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences).2012; 38(9): 547. CrossRef
Chemotherapy with Modified Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Metastatic Head and Neck Cancer
Jen-Tsun Lin, Guam-Min Lai, Tung-Hao Chang, Mu-Tai Liu, Chu-Ping Bi, Jer-Wei Wang, Mu-Kuan Chen
Advances in Therapy.2012; 29(1): 71. CrossRef
Heterogeneity of anticancer drug sensitivity in squamous cell carcinoma of the tongue
Minako Suzuki, Hiroshi Ishikawa, Akira Tanaka, Izumi Mataga
Human Cell.2011; 24(1): 21. CrossRef

11,472 View
66 Download
17 Crossref

First
Prev
Page of 1
Next
Last

Search